Imunopharm Technology Co., Ltd.
PrivateLast Round
Series E
Jan 8, 2025
Est. Valuation
$517.17M
Total Funding Raised
$97.1M
Company Overview
Imunopharm Technology Co., Ltd. is a biopharmaceutical company that develops innovative cell and gene therapies to treat serious diseases such as cancer and autoimmune disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Imunopharm Technology Co., Ltd. Comparables
Compare Imunopharm Technology Co., Ltd. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Hrain Biotechnology Co., Ltd. | 91% | |
| Juventas Cell Therapy Ltd. | 87% | |
| IASO Bio | 84% | |
Imunopharm Technology Co., Ltd. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series E | Jan 8, 2025 | ||||
| Series D Extension | Oct 31, 2022 | ||||
| Series D | Nov 24, 2021 | ||||
| Series C Extension | Dec 22, 2020 | ||||
| Series C Extension | Oct 19, 2020 | ||||
Series C | Jan 22, 2019 |
Imunopharm Technology Co., Ltd. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Thiel Capital | Series B, Series A |
| Legend Capital | Series B |
| Beijing Zhongguancun Science City Innovation Development Co., Ltd. | Series D Extension |
| China Taiping Insurance Group | Series E |
| 北京首都科技发展集团有限公司 | Series E, Series A |
| SDIC Venture Capital | Series E, Series D, Series C Extension |
| 太平医疗健康基金 | Series E |
Market signals
Structured signals derived from secondary market and firmographic data.
- Feb 26, 2025
Monthly visitors increased 52% MoM, from 355 to 539.
- Oct 1, 2024
Grew 29% QoQ, from 14 to 18 employees.
Imunopharm Technology Co., Ltd. Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Imunopharm Technology Co., Ltd.'s valuation, stock price, and market status.